Lilly: Superior Progression-Free Survival for Thyroid Cancer Therapy

 Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the multikinase inhibitors (MKIs) cabozantinib or vandetanib as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC). The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS). This result was based on a pre-specified interim efficacy analysis conducted by an independent data monitoring committee (IDMC). Adverse events observed on Retevmo were generally consistent with those identified across the previously reported Retevmo development program (LIBRETTO-001, LIBRETTO-121, LIBRETTO-321).

https://www.biospace.com/article/releases/lilly-s-retevmo-selpercatinib-demonstrates-superior-progression-free-survival-compared-to-approved-multikinase-inhibitors-in-ret-mutant-medullary-thyroid-cancer/